Study: Biotech no riskier for investors
Despite lower sales, lack of profits and heavy R&D spending, biotech companies that went public between 1997 and 2016 reached similar market caps as non-biotech companies, according to an academic study.
Gilead Covid-19 drug remdesivir benefited from $6.5B in NIH-funded basic research, study finds
Research on the drug's molecular target dates back to the 1950s. A spokesperson for Gilead noted that the company anticipates potentially investing more than $1 billion on the drug this year alone.
How Artera is Using Agentic AI to Humanize Patient Care
Artera President Tom McIntyre talks about the practical application of AI in healthcare.
Biopharma industry profitability in line with other R&D-heavy sectors, study finds
The study found that the sector's profitability is similar to those in areas like tech, even while it outpaces most of the S&P 500. Its lead author said that policy solutions to high drug prices need to balance affordability with ensuring drugmakers can make medicines available.